- Home
- CNO vs PTGX Comparison
CNO vs PTGX Comparison
Compare CNO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNO
- PTGX
- Stock Information
- Founded
- CNO 1979
- PTGX 2006
- Country
- CNO United States
- PTGX United States
- Employees
- CNO N/A
- PTGX N/A
- Industry
- CNO Accident &Health Insurance
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- CNO Finance
- PTGX Health Care
- Exchange
- CNO Nasdaq
- PTGX Nasdaq
- Market Cap
- CNO 3.8B
- PTGX 5.0B
- IPO Year
- CNO 1987
- PTGX 2016
- Fundamental
- Price
- CNO $41.26
- PTGX $85.30
- Analyst Decision
- CNO Hold
- PTGX Strong Buy
- Analyst Count
- CNO 5
- PTGX 9
- Target Price
- CNO $43.60
- PTGX $86.44
- AVG Volume (30 Days)
- CNO 554.4K
- PTGX 912.3K
- Earning Date
- CNO 11-03-2025
- PTGX 11-06-2025
- Dividend Yield
- CNO 1.64%
- PTGX N/A
- EPS Growth
- CNO 20.08
- PTGX N/A
- EPS
- CNO 2.98
- PTGX 0.72
- Revenue
- CNO $4,441,500,000.00
- PTGX $209,217,000.00
- Revenue This Year
- CNO N/A
- PTGX N/A
- Revenue Next Year
- CNO $3.27
- PTGX $140.23
- P/E Ratio
- CNO $13.90
- PTGX $117.38
- Revenue Growth
- CNO N/A
- PTGX N/A
- 52 Week Low
- CNO $34.63
- PTGX $33.31
- 52 Week High
- CNO $43.20
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- CNO 58.72
- PTGX 66.16
- Support Level
- CNO $40.08
- PTGX $76.70
- Resistance Level
- CNO $41.83
- PTGX $86.90
- Average True Range (ATR)
- CNO 0.89
- PTGX 3.20
- MACD
- CNO 0.11
- PTGX 0.30
- Stochastic Oscillator
- CNO 74.02
- PTGX 83.71
About CNO CNO Financial Group Inc.
CNO Financial Group Inc is a holding company for a group of insurance companies that offers middle-income American consumers insurance and securities products through exclusive agents, independent producers, and direct marketing. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.